-
-
-
-
-
-
-
Cogent Biosciences completes upsized $230 million public offering
-
-
-
-
-
-
-
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
-
-
-
-
-
-
-
Cogent Biosciences (COGT) Announces Proposed $125M Share Offering
-
-
-
-
-
-
-
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
-
-
-
-
-
-
-
Form S-3 Cogent Biosciences, Inc.
-
-
-
-
-
-
-
Form S-3/A Cogint, Inc.
-
71,086 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

